Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: W Shakespeare who wrote (1406)	12/7/1999 8:19:00 AM
From: Thai Chung	Read Replies (1) \| Respond to of 1754

MAYDAY! MAYDAY! VISX downed more than 30 pts. on instinet. Tight your seatbelts.

To: W Shakespeare who wrote (1406)	12/7/1999 8:55:00 AM
From: MGV	Respond to of 1754

By Tomi Kilgore & Brenon Daly, CBS MarketWatch Last Update: 8:22 AM ET Dec 7, 1999 NewsWatch Market Pulse NEW YORK (CBS.MW) -- Visx, Inc. saw its shares get pummeled in pre-market trading Tuesday after the International Trade Commission ruled that a competitor did not violate the Tariff Act of 1930. Today on CBS MarketWatch Stocks look to mixed open News Corp., Healtheon in $1 bln partnership U.S. view of Microsoft antitrust violations BT to offer unlimited Net access at a fixed price Sun to announce new software for Java program More top stories... CBS MarketWatch Columns Updated: 12/7/99 8:36:52 AM ET Visx (VISX: news, msgs) plunged 20 1/8, or 23 percent, to 68, according to Art Hogan, chief market analyst at Jefferies & Co. The ITC said in an "initial determination" that Nidek Co., and its U.S. subsidiaries was not in violation. Visx, which develops refractive laser technology for use in eye surgery, plans to file a petition with the ITC for a full review. If the review is granted, a final determination will be issued on March 6, 2000. Nidek is a privately held Japanese company that imports lasers into the United States. On Oct. 14, Advest Inc. analyst Theodore Huber conveyed his concerns on the impending ITC ruling on Nidek. The stock dropped 9.6 percent from the 80 21/32 level that day despite topping analyst earnings estimates. See related story.

To: W Shakespeare who wrote (1406)	12/7/1999 10:02:00 AM
From: MGV	Read Replies (1) \| Respond to of 1754

In point of fact, the Nidek verdict is completely irrelevant to BOL's and LASE's legal standing versus VISX. I disagree. The basis for the interim decision in the ITC involves an assessment of the validity of one of the two patents before the court and the intell. prop. relevance of the other. A third ground for the decision is not relevant outside of the ITC (that VISX failed to prove that the LVC industry is a "domestic industry." Any time the validity or relevance of VISX's IP is at issue, it is relevant to the industry and all of VISX's competitors.